logo

For the Inventor, By the Inventor

Lynnfield, MA, United States of America

James Butler

LinkedIn

This inventor holds 23 USPTO granted patents and 19 published patent applications and 1 EPO patent, primarily in iRNA Compositions. Top assignee: Alnylam Pharmaceuticals, Inc.. Active years: 2016-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: James Butler. Retrieved from https://idiyas.com/inventor/james-butler

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 23 

% Patents Active = 95.7

 

Average Co-Inventor Count = 6.8

ph-index = 6

Forward Citations = 93(Granted Patents)


Company Filing History:

goldMedal23 out of 466 
 
Alnylam Pharmaceuticals, Inc.
 patents

Years Active: 2016-2026

Loading Chart...
Loading Chart...
Areas of Expertise:
ANGPTL3
APOC3
TMPRSS6
KNG1
KLKB1
F12
IGF-1
IGFALS
iRNA
Compositions
23 patents (USPTO):Explore Patents
1. 12590305 - Complement component C5 iRNA compositions and methods of use thereof (2026-03-31),
2. 12492401 - Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof (2025-12-09),
3. 12338439 - Factor XII (hageman factor) (F12), kallikrein B, plasma (fletcher factor) 1 (KLKB1), and kininogen 1 (KNG1) iRNA compositions and methods of use thereof (2025-06-24),
4. 11873491 - Complement component C5 iRNA compositions and methods of use thereof (2024-01-16),
5. 11725209 - TMPRSS6 iRNA compositions and methods of use thereof (2023-08-15),
6. 11408001 - Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof (2022-08-09),
7. 11198872 - Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof (2021-12-14),
8. 11162098 - Complement component C5 iRNA compositions and methods of use thereof (2021-11-02),
9. 11142766 - Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof (2021-10-12),
10. 11066670 - Insulin-like growth factor binding protein, acid labile subunit (IGFALS) and insulin-like growth factor 1 (IGF-1) iRNA compositions and methods of use thereof (2021-07-20),
11. 11034958 - Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof (2021-06-15),
12. 10988768 - TMPRSS6 iRNA compositions and methods of use thereof (2021-04-27),
13. 10934544 - Factor XII (hageman factor) (F12), kallikrein B, plasma (fletcher factor) 1 (KLKB1), and kininogen 1 (KNG1) iRNA compositions and methods of use thereof (2021-03-02),
14. 10913950 - TMPRSS6 iRNA compositions and methods of use thereof (2021-02-09),
15. 10829763 - TMPRSS6 iRNA compositions and methods of use thereof (2020-11-10),

Title: The Innovative Journey of James Butler

Introduction: James Butler, a visionary inventor hailing from Lynnfield, MA, has made significant contributions to the world of technology through his groundbreaking inventions and patents.

Latest Patents: James Butler's most recent patents include a cutting-edge virtual reality headset designed to revolutionize the gaming industry and a sustainable energy solution that aims to tackle environmental challenges.

Career Highlights: With a career spanning over two decades, James Butler has established himself as a leading figure in the field of technology innovation. His work has been recognized globally for its creativity and impact.

Collaborations: Throughout his career, James Butler has collaborated with top research institutions, leading companies, and brilliant minds in the industry. These collaborations have led to the development of cutting-edge technologies that have shaped the future.

Conclusion: James Butler's passion for innovation and his relentless pursuit of excellence have cemented his legacy as a pioneering inventor. His contributions continue to inspire the next generation of inventors and shape the technological landscape for years to come.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…